Abstract

BackgroundAutologous haematopoietic stem cell transplantation (AHSCT) is a highly effective treatment for multiple sclerosis (MS). The impact of previous long-lasting disease-modifying treatments (DMT) for safety and efficacy of AHSCT is...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss
Jarmila Szilasiová ... Miriam Fedičová
Multiple Sclerosis | VOL. 27
Jarmila Szilasiová, et. al.Jarmila Szilasiová ... Miriam Fedičová
26 Feb 2021
The COVID-19 pandemic and the use of MS disease-modifying therapies
Gavin Giovannoni ... Julian Gold
Multiple sclerosis and related disorders | VOL. 39
Gavin Giovannoni, et. al.Gavin Giovannoni ... Julian Gold
27 Mar 2020
Neurofilament Light Chain Levels Are Associated with Disease Activity Determined by No Evident Disease Activity in Multiple Sclerosis Patients
Jarmila Szilasiová ... Pavol Mikula
European neurology | VOL. 84
Jarmila Szilasiová, et. al.Jarmila Szilasiová ... Pavol Mikula
25 May 2021
SARS-CoV-2 pandemic as a model to assess the relationship between intercurrent viral infections and disease activity in Multiple Sclerosis: A propensity score matched case-control study.
Marco Vercellino ... Anastasia Alteno
Multiple sclerosis and related disorders | VOL. 74
Marco Vercellino, et. al.Marco Vercellino ... Anastasia Alteno
01 Jun 2023
View more papers

More From: Journal of Neurology, Neurosurgery & Psychiatry

Paper Title
Journal
Date
Author
Vitamin D affects the risk of disease activity in multiple sclerosis
Antonino Giordano ... Federica Esposito
Journal of Neurology, Neurosurgery & Psychiatry | VOL. -
Antonino Giordano, et. al.Antonino Giordano ... Federica Esposito
13 Jul 2024
Induction cyclophosphamide with maintenance immunosuppression in high-risk myasthenia gravis: long-term follow-up and safety profile
Fiona Chan ... Stephen W Reddel
Journal of Neurology, Neurosurgery & Psychiatry | VOL. -
Fiona Chan, et. al.Fiona Chan ... Stephen W Reddel
04 Jul 2024
Cyclophosphamide for myasthenia gravis: a comeback?
Carolina Barnett-Tapia ... Hans D Katzberg
Journal of Neurology, Neurosurgery & Psychiatry | VOL. -
Carolina Barnett-Tapia, et. al.Carolina Barnett-Tapia ... Hans D Katzberg
04 Jul 2024
Predictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease
Akash Virupakshaiah ... Emmanuelle Waubant
Journal of Neurology, Neurosurgery & Psychiatry | VOL. -
Akash Virupakshaiah, et. al.Akash Virupakshaiah ... Emmanuelle Waubant
04 Jul 2024
View more papers